Recent Publications by Celgene Corporation: |
Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone.
PURPOSE: We conducted a retrospective analysis of the survival effect of... | 11th November, 2009
| Division of Hematology, Blood/Marrow Transplant and Myeloma Program,
| J Clin Oncol. 2009 Nov 9.
DOI Direct Link |
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Lenalidomide and pomalidomide have both been evaluated clinically for... | 8th October, 2009
| Celgene, San Diego, California 92121, USA.
| Cancer Res. 2009 Sep 15;69(18):7347-56. Epub 2009 Sep 8.
DOI Direct Link |
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma.
PURPOSE: Lenalidomide and bortezomib are active in relapsed and... | 30th September, 2009
| Department of Medical Oncology, Dana-Farber Cancer Institute; and Beth
| J Clin Oncol. 2009 Nov 9.
DOI Direct Link |
Determination of the residual ethanol in hydroalcoholic sealed hard gelatin capsules by static headspace gas chromatography with immiscible binary solvents.
Static headspace gas chromatography (HS-GC) with immiscible binary... | 11th September, 2009
| Analytical Research and Development, Celgene Corporation, Summit, NJ
| J Chromatogr A. 2009 Apr 10;1216(15):3328-36. Epub 2009 Feb 21.
DOI Direct Link |
Thalidomide chemotherapy-induced peripheral neuropathy: actual status and new perspectives with thalidomide analogues derivatives.
IMiDs compounds are a class of analogues of thalidomide, with greater... | 20th August, 2009
| Medical Department, Celgene S.r.l., Corso Garibaldi 86 - 20121 Milano,
| Mini Rev Med Chem. 2009 Jun;9(7):760-8.
|
Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases.
IMiDs immunomodulatory drugs, including lenalidomide and pomalidomide... | 28th July, 2009
| Celgene, San Diego, CA 92121, USA.
| Blood. 2009 Jul 9;114(2):338-45. Epub 2009 May 5.
DOI Direct Link |
Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth.
Protein kinase CK2 (CK2) is a highly conserved and ubiquitous... | 25th July, 2009
| Celgene Corporation, 4550 Towne Centre Court, San Diego, CA, 92121, USA,
| Mol Cell Biochem. 2009 Jul 21.
DOI Direct Link |
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Lenalidomide (Revlimid) is approved for the treatment of... | 14th July, 2009
| Department of Immunotherapeutics, Celgene Corporation, 86 Morris Avenue,
| Microvasc Res. 2009 Mar;77(2):78-86. Epub 2008 Sep 4.
DOI Direct Link |
Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.
BACKGROUND AND OBJECTIVES: Multiple myeloma treatment with... | 2nd June, 2009
| Global Drug Safety, Celgene Corporation, Summit, New Jersey, USA.
| Clin Drug Investig. 2009;29(3):161-71. doi:
|
Drug delivery to the posterior segment of the eye IV: theoretical formulation of a drug delivery system for subconjunctival injection.
PURPOSE: The aim of the current study was to provide insights on the... | 1st May, 2009
| Pharmaceutical and Analytical Development, Novartis Pharmaceuticals
| J Ocul Pharmacol Ther. 2009 Feb;25(1):29-37.
DOI Direct Link |
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2 ,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.
In this communication, we report the discovery of 1S (apremilast), a novel... | 21st April, 2009
| Drug Discovery Department, Celgene Corporation, 86 Morris Avenue, Summit,
| J Med Chem. 2009 Mar 26;52(6):1522-4.
DOI Direct Link |
Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
PURPOSE: To assess the potential for drug-drug interactions between... | 18th April, 2009
| Early Drug Development, Celgene Corporation, Summit, NJ 07901, USA.
| Cancer Chemother Pharmacol. 2009 May;63(6):1171-5. Epub 2008 Nov 23.
DOI Direct Link |
Are myelodysplastic syndromes and acute myeloid leukemia one disease?
PURPOSE: To assess the potential for drug-drug interactions between... | 28th February, 2009
| Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901 USA.
| Leuk Res. 2009 Mar;33(3):351-4. Epub 2008 Nov 8.
DOI Direct Link |
RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide.
Lenalidomide (Revlimid) is an immunomodulatory drug and an analogue of... | 7th January, 2009
| Global Drug Safety, Celgene Corporation, Summit, New Jersey 07901, USA.
| Drug Saf. 2008;31(9):743-52.
|
Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling.
Targeting the IL-13 pathway appears to be a viable approach to ameliorate... | 17th December, 2008
| Celgene
| Curr Opin Investig Drugs. 2008 Nov;9(11):1180-4.
|
